Skip to main content
Identifying Counterfeit Pharmaceuticals

Identifying Counterfeit Pharmaceuticals

Streamline the Analysis and Identification of Counterfeit Drugs

The prevalence of counterfeit pharmaceuticals is a growing global concern. In certain regions of the world, the percentage of counterfeit pharmaceuticals present in the consumer marketplace can be as high as 50%*. Even at lower frequency, counterfeit drugs are a concern. Counterfeit medicines may be contaminated, contain the wrong active pharmaceutical ingredient (API), the incorrect dose, or no API at all. They may also contain ingredients that are not on the label or may be supplied with inappropriate packaging. Even slight variations in the drug formulation can result in the medication being processed differently in the body. Counterfeit pharmaceuticals can be harmful to patients and need to be identified.

To protect patient safety, screening programs are in place to identify counterfeit pharmaceuticals. Analytical methods tend to rely on traditional laboratory analysis techniques, including liquid chromatography and wet chemistry. Depending on the drug, different LC techniques have been employed successfully, including 2D-LC. In recent years, screening methods such as Fourier transform infrared (FTIR) and Raman spectroscopy have been used for counterfeit drug screening. These spectroscopy techniques are fast and easy to use, requiring less expertise once an established method has been developed.

Agilent offers a range of instruments, methods, software, and services to help you streamline your analysis and achieve results you can trust.

Follow Agilent’s Pharma LinkedIn Showcase:
Follow us on LinkedIn for Continuous up to date Pharma news, events, publications and more

* Counterfeit drugs and medical devices in developing countries Dovepress 24 March 2014 Volume 2014:5 Pages 11—22